Mangoceuticals, Inc.
MGRX
$2.49
-$0.08-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -56.96% | -45.60% | 15.58% | 112.61% | 2,646.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -56.96% | -45.60% | 15.58% | 112.61% | 2,646.07% |
| Cost of Revenue | -75.34% | -49.60% | 72.64% | 53.33% | 2,382.93% |
| Gross Profit | -43.83% | -42.81% | -19.86% | 157.69% | 2,810.20% |
| SG&A Expenses | -26.96% | -6.09% | -11.33% | -13.74% | 184.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.07% | -8.54% | -2.19% | 13.63% | 210.55% |
| Operating Income | -6.28% | 2.65% | 3.32% | -8.46% | -183.18% |
| Income Before Tax | 24.12% | -11.13% | -4.70% | 7.55% | -281.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.12% | -11.13% | -4.70% | 7.55% | -281.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.13% | -11.10% | -4.68% | 7.55% | -281.18% |
| EBIT | -6.28% | 2.65% | 3.32% | -8.46% | -183.18% |
| EBITDA | 25.69% | 2.27% | 3.19% | -8.47% | -182.75% |
| EPS Basic | 45.01% | 41.44% | 36.74% | 54.41% | -160.54% |
| Normalized Basic EPS | 62.02% | 41.44% | 36.74% | 54.42% | -160.53% |
| EPS Diluted | 45.01% | 41.44% | 36.74% | 54.41% | -160.54% |
| Normalized Diluted EPS | 62.02% | 41.44% | 36.74% | 54.42% | -160.53% |
| Average Basic Shares Outstanding | 99.73% | 89.69% | 65.48% | 102.80% | 46.31% |
| Average Diluted Shares Outstanding | 99.73% | 89.69% | 65.48% | 102.80% | 46.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |